AZN.L - AstraZeneca PLC

LSE - LSE Delayed price. Currency in GBp
5,007.00
-29.00 (-0.58%)
At close: 5:10PM GMT
Stock chart is not supported by your current browser
Previous close5,036.00
Open5,008.00
Bid4,976.00 x 6100
Ask5,230.00 x 13000
Day's range4,989.50 - 5,108.89
52-week range3,996.00 - 5,520.00
Volume1,571,002
Avg. volume2,275,227
Market cap63.386B
Beta0.63
PE ratio (TTM)16.42
EPS (TTM)304.90
Earnings date2 Feb 2018
Forward dividend & yield2.79 (4.51%)
Ex-dividend date2017-08-10
1y target est68.14
  • Reutersyesterday

    Brexit gets real for drugmakers as regulator moves to Amsterdam

    Drugmakers are racing to implement Brexit contingency plans to prepare for a jolt to their regulatory system as the European Medicines Agency is uprooted from London to Amsterdam. Pharmaceutical companies, used to decade-long drug development cycles, and EMA staff face a mountain of paperwork to keep medicine supplies flowing without disruption. Amsterdam maybe the least-worst option for staff retention, with 81 percent of EMA staff surveyed ready to move to the Dutch city, but there is still a real fear of bureaucratic logjams given the upheaval and ultra-tight schedule dictated by Brexit.

  • Top Research Reports on Walmart, NVIDIA and Procter & Gamble
    Zacks2 days ago

    Top Research Reports on Walmart, NVIDIA and Procter & Gamble

    Top Research Reports on Walmart, NVIDIA and Procter & Gamble

  • Reuters2 days ago

    EU drugs agency move to Amsterdam minimises likely staff losses

    Amsterdam's success in winning the battle to host the European Medicines Agency (EMA), which is relocating from London because of Brexit, was welcomed by drug manufacturers on Monday hoping for the least disruption due to staff losses at the regulator. Amsterdam was the most popular of 19 potential new homes for the drugs watchdog in a recent survey of staff, with 81 percent of them saying they would be willing to move to the Dutch city. EuropaBio, representing Europe's biotech sector, said it was happy to see Amsterdam selected.

  • Reuters - UK Focus2 days ago

    EU drugs agency move to Amsterdam minimises likely staff losses

    Amsterdam's success in winning the battle to host the European Medicines Agency (EMA), which is relocating from London because of Brexit, was welcomed by drug manufacturers on Monday hoping for the least disruption due to staff losses at the regulator. Amsterdam was the most popular of 19 potential new homes for the drugs watchdog in a recent survey of staff, with 81 percent of them saying they would be willing to move to the Dutch city. EuropaBio, representing Europe's biotech sector, said it was happy to see Amsterdam selected.

  • Reuters2 days ago

    FTSE recoups early losses as cyclicals recover

    By Kit Rees and Helen Reid LONDON (Reuters) - Britain's top share index recovered from earlier losses to inch higher at the start of the week as cyclical sectors made a comeback, though the UK market lagged ...

  • Reuters - UK Focus2 days ago

    Britain's FTSE recoups early losses as cyclicals recover

    Britain's top share index recovered from earlier losses to inch higher at the start of the week as cyclical sectors made a comeback, though the UK market lagged European benchmarks and Shire was a loser ...

  • Reuters - UK Focus2 days ago

    Roche stock up $12 bln on cancer, haemophilia trials; rivals hit

    Roche shares were lifted on Monday by two trial wins for its new cancer and haemophilia drugs, potential blockbusters that the Swiss drugmaker is counting on to offset shrinking revenue from older medicines. Along with Roche's multiple sclerosis medicine Ocrevus, the drugs are pillars of Chief Executive Severin Schwan's plan to offset the patent expiry of top-sellers Rituxan, Avastin and Herceptin which account for $20 billion in annual sales. Roche said Tecentriq had cut the risk of lung cancer worsening when mixed with other treatments, while haemophilia agent Hemlibra had reduced bleeds in a new group of patients.

  • Forbes2 days ago

    For Parkinson's Patients Like Jesse Jackson, Artificial Intelligence Shows Real Promise

    US civil rights activist Jesse Jackson disclosed that he has been diagnosed with Parkinson’s disease. Unfortunately for Jackson, and more than 10 million worldwide living with Parkinson's, there's no cure. However, a new partnership between AstraZeneca and Berg believes AI will be able to prevent it

  • Reuters2 days ago

    Roche win boosts case for adding chemo to cancer immunotherapy

    Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism. News that Roche's immune system-boosting drug Tecentriq delayed lung cancer progression when given alongside chemo and its older drug Avastin validates the approach for the first time in a large Phase III clinical trial. It is a significant milestone for physicians, patients and investors, who are trying to assess the competitive landscape as drugmakers race to develop better ways to fight tumours in previously untreated lung cancer.

  • Reuters - UK Focus2 days ago

    Roche win boosts case for adding chemo to cancer immunotherapy

    Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism. News that Roche's immune system-boosting drug Tecentriq delayed lung cancer progression when given alongside chemo and its older drug Avastin validates the approach for the first time in a large Phase III clinical trial.

  • Market Realist2 days ago

    AstraZeneca’s Other Products in 3Q17

    The Other Products segment reported revenues of $991 million during 3Q17, a 17% fall in constant exchange rates compared to 3Q16.

  • Market Realist2 days ago

    Performance of AstraZeneca’s Oncology Segment in 3Q17

    AstraZeneca’s (AZN) Oncology segment reported revenues of ~$1 billion during 3Q17, a 19% growth at constant exchange rates.

  • Reuters - UK Focus2 days ago

    Britain's FTSE stuck at 7-week lows as cyclicals, Shire declines

    Britain's top share index made a muted start to the week, holding at seven-week lows as cyclical sectors were on the back foot and Shire was a loser among health stocks. The blue chip FTSE 100 index was ...

  • Market Realist5 days ago

    AstraZeneca’s Respiratory Segment in 3Q17

    AstraZeneca’s (AZN) Respiratory segment is one of its key growth platforms. For 3Q17, the segment's revenues fell 2% at constant exchange rates to ~$1.1 billion.

  • Cancer Space Update: Label Expansion for Three Major Drugs
    Zacks5 days ago

    Cancer Space Update: Label Expansion for Three Major Drugs

    This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.

  • Market Realist5 days ago

    AstraZeneca’s Cardiovascular and Metabolic Diseases Segment

    Brilinta reported 36% growth in revenues at constant exchange rates to $284 million, while foreign exchange impacted its revenues positively by 1% during 3Q17.

  • Market Realist5 days ago

    How AstraZeneca’s Growth Platforms Performed in 3Q17

    The Respiratory segment reported a 2% fall in revenues at constant exchange rates to ~$1.1 billion during 3Q17.

  • Texas Lawsuit Claims This Drugmaker Pushed Antipsychotic to Kids
    Bloomberg5 days ago

    Texas Lawsuit Claims This Drugmaker Pushed Antipsychotic to Kids

    AstraZeneca Plc is in talks to settle a Texas lawsuit claiming that the company fleeced the state’s Medicaid program by fraudulently marketing one of its top drugs, according to court filings.

  • Market Realist6 days ago

    AstraZeneca’s Performance by Segment in 3Q17

    The CVMD segment reported a 4% fall in revenues at constant exchange rates to ~$1.8 billion during 3Q17.

  • Market Realist6 days ago

    Why AstraZeneca’s Revenues Rose in 3Q17

    AstraZeneca's (AZN) overall revenue growth was 9%, driven by a substantial growth in externalization revenues to $1.~4 billion, partially offset by a 2% fall in product sales.

  • Market Realist6 days ago

    AstraZeneca’s Valuation after 3Q17 Earnings

    In 3Q17, AstraZeneca reported EPS of $0.56 on revenues of $6.2 billion compared to estimates of $0.71 for EPS on revenues of $6 billion.

  • Reuters - UK Focus6 days ago

    AstraZeneca ticks another box as U.S. approves severe asthma drug

    AstraZeneca has achieved another milestone in rebuilding its drug portfolio with U.S. approval of a drug for severe asthma as the company battles to put patent losses on older medicines behind it. The U.S. Food and Drug Administration's (FDA) decision to endorse benralizumab, which will be marketed under the name Fasenra, follows a positive recommendation for the product in Europe on Friday. Shares (Berlin: DI6.BE - news) in AstraZeneca were 1 percent higher on Wednesday following the overnight news.

  • AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio
    Zacks6 days ago

    AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio

    AstraZeneca's (AZN) drug Faslodex received FDA approval for a new indication.

  • Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo
    Zacks6 days ago

    Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo

    Key highlights this week include the FDA approval of AstraZeneca's (AZN) severe asthma drug and Bayer's collaboration with Loxo for cancer.

  • Reuters - UK Focus6 days ago

    BUZZ-AstraZeneca: cancer immunotherapy gets positive NEJM review

    ** AstraZeneca's immunotherapy drug Imfinzi enjoys enthusiastic editorial review in influential New England Journal of Medicine, following positive data reported in September from the Pacific stage III ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes